BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22221250)

  • 1. Amplified segment in the 'Down syndrome critical region' on HSA21 shared between Down syndrome and euploid AML-M0 excludes RUNX1, ERG and ETS2.
    Canzonetta C; Hoischen A; Giarin E; Basso G; Veltman JA; Nacheva E; Nizetic D; Groet J
    Br J Haematol; 2012 Apr; 157(2):197-200. PubMed ID: 22221250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia.
    Weber S; Haferlach C; Jeromin S; Nadarajah N; Dicker F; Noël L; Zenger M; Alpermann T; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2016 Feb; 55(2):148-57. PubMed ID: 26542308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased dosage of the RUNX1/AML1 gene: a third mode of RUNX leukemia?
    Osato M; Ito Y
    Crit Rev Eukaryot Gene Expr; 2005; 15(3):217-28. PubMed ID: 16390318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
    Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
    Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.
    Baldus CD; Liyanarachchi S; Mrózek K; Auer H; Tanner SM; Guimond M; Ruppert AS; Mohamed N; Davuluri RV; Caligiuri MA; Bloomfield CD; de la Chapelle A
    Proc Natl Acad Sci U S A; 2004 Mar; 101(11):3915-20. PubMed ID: 15007164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Array comparative genome hybridization analysis of acute lymphoblastic leukaemia and acute megakaryoblastic leukaemia in patients with Down syndrome.
    Lo KC; Chalker J; Strehl S; Neat M; Smith O; Dastugue N; Kearney L; Izraeli S; Kempski H; Cowell JK
    Br J Haematol; 2008 Sep; 142(6):934-45. PubMed ID: 18557744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.
    Maicas M; Vázquez I; Vicente C; García-Sánchez MA; Marcotegui N; Urquiza L; Calasanz MJ; Odero MD
    Oncogene; 2013 Apr; 32(16):2069-78. PubMed ID: 22689058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The proto-oncogene ERG in megakaryoblastic leukemias.
    Rainis L; Toki T; Pimanda JE; Rosenthal E; Machol K; Strehl S; Göttgens B; Ito E; Izraeli S
    Cancer Res; 2005 Sep; 65(17):7596-602. PubMed ID: 16140924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the transcription factor ETS2 in brain of patients with Down syndrome--evidence against the overexpression-gene dosage hypothesis.
    Greber-Platzer S; Schatzmann-Turhani D; Cairns N; Balcz B; Lubec G
    J Neural Transm Suppl; 1999; 57():269-81. PubMed ID: 10666682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant aberrant overexpression of RUNX1 and NCAM in regenerating bone marrow of myeloid leukemia of Down's syndrome.
    Langebrake C; Klusmann JH; Wortmann K; Kolar M; Puhlmann U; Reinhardt D
    Haematologica; 2006 Nov; 91(11):1473-80. PubMed ID: 17043020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia.
    Coskun E; von der Heide EK; Schlee C; Kühnl A; Gökbuget N; Hoelzer D; Hofmann WK; Thiel E; Baldus CD
    Leuk Res; 2011 Feb; 35(2):208-13. PubMed ID: 20570349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute multilineage (B/myeloid) leukemia with RUNX1 duplication/amplification and hypereosinophilia.
    Holmes A; Coviello J; Velagaleti G
    Eur J Haematol; 2014 Nov; 93(5):449-52. PubMed ID: 24912843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trisomic dose of several chromosome 21 genes perturbs haematopoietic stem and progenitor cell differentiation in Down's syndrome.
    De Vita S; Canzonetta C; Mulligan C; Delom F; Groet J; Baldo C; Vanes L; Dagna-Bricarelli F; Hoischen A; Veltman J; Fisher EM; Tybulewicz VL; Nizetic D
    Oncogene; 2010 Nov; 29(46):6102-14. PubMed ID: 20697343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status.
    Hämäläinen M; Juvonen V; Häikiö S; Lakkala T; Johansson J; Pelliniemi TT; Salmi TT; Remes K; Kairisto V
    Eur J Haematol; 2010 Oct; 85(4):361-2. PubMed ID: 20546020
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute myeloid leukemia: a central role for the ETS factor ERG.
    Martens JH
    Int J Biochem Cell Biol; 2011 Oct; 43(10):1413-6. PubMed ID: 21664289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
    Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
    Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
    Harada Y; Harada H
    J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
    Migas A; Savva N; Mishkova O; Aleinikova OV
    Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.